Metabolomics has become a key tool for understanding the effects of external or pathological stressors on biological systems. Over the past decade, both targeted and untargeted metabolomics have demonstrated tremendous potential. They enable the analysis of phenotypic changes in metabolites, and provide comprehensive information on the outcomes of normal physiological functions and the effects of various pathophysiological stimuli in tissues, cells, and bodily fluids. In the context of drug discovery, systems biology aims to combine ''omics'' approaches with bioinformatics methods to enhance the success rate of drug candidate screening and the identification of clinical indications. Untargeted metabolomics is a ‘hypothesis-generating discovery strategy’ that identifies metabolites and detects disturbances (including early signs of disease) by comparing sample groups (e.g. case versus control groups). Targeted metabolomics helps to gather critical information in the life sciences and reveals new strategies for treating major clinical diseases such as cancer, cardiovascular disease, diabetes and drug toxicity. Due to its importance in biomarker discovery, research is currently focused on enhancing the translational potential of non-targeted metabolomics. Both approaches have their own advantages and disadvantages, and they are usually employed together to identify differentially expressed metabolites and accurately determine their masses. This enables in-depth research and analysis of metabolic biomarkers. Targeted and non-targeted metabolomics are widely used in the identification of foods, research into diseases, the validation of animal models, the discovery of biomarkers, the diagnosis of diseases, the development of drugs, the screening of drugs, the evaluation of drugs, and clinical research into plant and microbial metabolism. Creative Diagnostics now offers untargeted metabolomics services based on high-resolution LC-MS/MS technology, supporting research projects in the pharmaceutical and biotechnology industries, academia, and translational research. Through the integration of optimized sample preparation, high-resolution mass spectrometry, advanced bioinformatics and biological interpretation, Creative Diagnostics has developed a thorough workflow that allows researchers to identify metabolic changes related to disease progression, drug responses and cellular functions. The platform supports a wide range of applications, including global metabolite profiling, differential metabolite analysis, biomarker discovery, mechanism of action studies, drug efficacy assessment, host-pathogen interaction studies, immunometabolism research and multi-omics integration. Combining high-sensitivity LC-MS/MS data acquisition with robust statistical analysis, Creative Diagnostics’ untargeted metabolomics services reveal metabolic pathway-level changes that are difficult to detect using targeted analysis methods alone. Additionally, Creative Diagnostics implements rigorous quality control (QC) procedures throughout the analytical workflow to ensure consistent and reproducible data. These QC strategies include using pooled QC samples, monitoring system suitability to track instrument performance, normalizing with internal standards, and correcting for batch effects. To learn more about Creative Diagnostics'' Untargeted Metabolomics Services, please visit: https://qbd.creative-diagnostics.com/untargeted-metabolomics-services.html. About Creative Diagnostics Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has expanded its research support suite and announced a comprehensive range of products and services targeted at the Bundibugyo Virus (BDBV). These offerings aim to accelerate viral detection, characterization, and countermeasure development, thereby advancing vaccine candidate evaluation, antiviral discovery, and diagnostic assay development. Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegavirales. The Filoviridae family comprises three genera: Ebola virus, Marburg virus and Cueva virus. The Ebola virus genus is further subdivided into five species, each represented by a unique virus: Taï Forest Ebola virus (TAFV), Reston Ebola virus (RESTV), Sudan Ebola virus (SUDV), Bundibugyo Ebola virus (BDBV), and Zaire Ebola virus (EBOV). EBOV is the most prominent of these. BDBV is considered a less virulent Ebola virus due to its lower case fatality rate in human and animal outbreaks (25% to 51%). In contrast, the case fatality rate following Ebola virus infection in non-human primates is almost always fatal. While in-depth transcriptomic analyses have been conducted on samples from human patients and non-human primates infected with the Ebola virus, no such studies have been conducted on the Bundibugyo virus. The clinical manifestations of Ebola virus infection in humans and non-human primates (NHPs) are similar and include viremia, cytokine storm and consumptive coagulopathy, which can lead to septic shock and multiple organ failure. The virus initially replicates in monocytes and dendritic cells before spreading to hepatocytes, endothelial cells and epithelial cells. In May 2026, the World Health Organization (WHO) received a report of a highly fatal Bondibougio virus outbreak in Mongbwalu Health Zone, Ituri Province, Democratic Republic of the Congo (DRC), which resulted in deaths among healthcare workers. The Bondibougio virus forms filamentous viral particles and is closely related to the Zaire Ebola virus. It is one of several viruses that can cause Ebola in humans, presenting as viral haemorrhagic fever. Unlike Ebola virus disease, there are currently no approved vaccines or specific treatments for the Bondibougio virus, but early supportive care can save lives. This outbreak has once again drawn global attention to Ebola, highlighting the urgent need to develop effective diagnostic and preventive products. Recognizing the urgent need for more effective tools to combat BDBV, Creative Diagnostics is monitoring the current outbreak closely and has swiftly introduced a range of products to support BDBV infection and vaccine research, including antibodies, ELISA kits, RT-PCR kits, and nucleic acid standard references. Creative Diagnostics will continue to provide research solutions to assist scientists, public health researchers and biotechnology organizations in deeper understanding of this emerging pathogen. To learn more about Creative Diagnostics'' research products and outbreak response reagents, please visit https://www.creative-diagnostics.com/bundibugyo-virus-bdbv-outbreak-response.htm. About Creative Diagnostics Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers'' assay development and manufacturing needs.

Respiratory Syncytial Virus Animal Model Services for Antiviral and Vaccine Discovery

Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics

Hantavirus Research Reagents and Products to Accelerate Global Diagnostic and Vaccine Research